ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1008

Advantageous Effect of an Endogenous Retroviral Envelope Protein in Systemic Lupus Erythematosus with Ex Vivo and In Vivo Anti-Inflammatory Potential

Anne Troldborg1,2, Magdalena Janina Laska3, Ellen-Margrethe Hauge4,5, Shervin Bahrami6 and Kristian Stengaard-Pedersen7,8, 1clinical medicine, Aarhus University, Aarhus, Denmark, 2Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 3Biomedicine, Aarhus University, Aarhus, Denmark, 4Dept. of Anatomy, Aarhus University, Aarhus, Denmark, 5Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 6Clinical Medicine, Aarhus University, Aarhus, Denmark, 7Clinical medicine, Aarhus University, Aarhus, Denmark, 8Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Animal models, Arthritis, autoimmune diseases, pathogenesis and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Innate Immunity and Rheumatic Disease

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Human Endogenous Retroviruses (HERVs) are remnants of retroviral infections in the human germline. Most, but not all, HERV genes have become inactive by accumulation of mutations. The presence of open reading frames (ORFs) in a few select HERV genes, suggest an evolutionary advantage for the host in maintaining the protein coding capacity. We investigated whether differences could be detected between upregulation of a panel of ENV-proteins in patients with Systemic Lupus Erythematosus (SLE) compared to healthy controls. Further, we examined a peptide form of the highest upregulated ENV-protein for an anti-inflammatory potential in vitro, ex vivo and in vivo

Methods: 45 patients fulfilling the ACR criteria for SLE and 50 age and gender matched blood donors, were included consecutively. By real time PCR, we analyzed the transcriptome of 11 genes with coding capacity for complete envelope protein. Subsequently, we cloned the Env59 gene to examine if it retained its retroviral fusion protein activity. Sequence analysis of the protein identified an immune suppressive domain (ISD). A corresponding peptide was synthesized and examined in vitro for immune suppressive activity on stimulated experimental cell lines and ex vivo on human PBMCs from patients with SLE and Rheumatoid Arthritis. Next, in two separate treatment experiments, we tested the anti-inflammatory potential of the peptide in vivo in an experimental model of arthritis, the Sakaguchi mouse (first experiment n=15, second n=40). Mice were treated daily for 4 weeks. Arthritis scoring was performed blinded. At termination, hind paws were fixated in ethanol for histology and stained with Masson-Golden trichrome.

Results: We found that the HERV-H derived Env gene (Env59) was highly expressed in SLE patients. Further, that expression of Env59 showed negative correlation with the central inflammatory protein IL-6 (P=0.0065). The peptide version of the Env59 ISD had anti-inflammatory activity and ability to lower IL-6 levels in vitro and ex vivo. Lastly, in two independent in vivo experiments of experimental arthritis, we illustrated the peptide significantly lowered arthritis score (p<0.05) in treated versus untreated mice. The reduction in arthritis was confirmed measuring serum amyloid A3 as a biomarker for inflammation and by histology in mice treated with saline compared to peptide-treated mice.

Conclusion: We demonstrated an upregulation of Env59 in SLE patients compared to healthy controls, and that ENV59 expression was negatively correlated to IL-6 expression in SLE patients. With a synthetic peptide derived from the ISD domain of the retroviral gene we illustrated an anti-inflammatory potential of the peptide in vitro, ex vivo and in vivo. We propose the peptide represents a possible new treatment strategy for inflammatory diseases.


Disclosure: A. Troldborg, StemGuard aps, 4; M. J. Laska, StemGuard aps, 3; E. M. Hauge, None; S. Bahrami, CEO of StemGuard aps, 3; K. Stengaard-Pedersen, StemGuard aps, 4.

To cite this abstract in AMA style:

Troldborg A, Laska MJ, Hauge EM, Bahrami S, Stengaard-Pedersen K. Advantageous Effect of an Endogenous Retroviral Envelope Protein in Systemic Lupus Erythematosus with Ex Vivo and In Vivo Anti-Inflammatory Potential [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/advantageous-effect-of-an-endogenous-retroviral-envelope-protein-in-systemic-lupus-erythematosus-with-ex-vivo-and-in-vivo-anti-inflammatory-potential/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/advantageous-effect-of-an-endogenous-retroviral-envelope-protein-in-systemic-lupus-erythematosus-with-ex-vivo-and-in-vivo-anti-inflammatory-potential/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology